MediWound (NASDAQ:MDWD – Get Rating)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $23.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 110.43% from the stock’s current price.
Several other analysts have also weighed in on MDWD. Cowen increased their price target on MediWound from $6.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, December 30th. Maxim Group started coverage on MediWound in a report on Thursday, December 22nd. They set a “buy” rating on the stock. Finally, StockNews.com assumed coverage on MediWound in a report on Thursday. They set a “hold” rating on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.40.
MediWound Stock Performance
NASDAQ:MDWD opened at $10.93 on Friday. The stock’s fifty day moving average is $12.69 and its 200 day moving average is $11.47. MediWound has a fifty-two week low of $8.05 and a fifty-two week high of $17.08. The firm has a market capitalization of $63.61 million, a PE ratio of -2.95 and a beta of 0.98.
Institutional Trading of MediWound
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
- Get a free copy of the StockNews.com research report on MediWound (MDWD)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.